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Abstract
Background: The worldwide expansion of macrolide-resistant Mycoplasma genitalium (MG) in cases of genital
infections has led to an increased recurrence rate of these infections after first-line azithromycin treatment. By
detecting the presence of azithromycin-resistant MG, the patient’s antibiotic treatment can be targeted and the
spread of resistance prevented. With this aim in mind, macrolide-resistance detection kits are helpful tools for the
physician.
Methods: Azithromycin resistance mutations in MG are targeted using a four-color multiplex real-time RT-PCR
assay. Tested targets include plasmid DNA (as positive controls) as well as macrolide-sensitive and macrolide-
resistant genomic DNA from characterized cell lines and clinical samples.
Results: The analytical data presented here were generated from plasmid DNA and genomic RNA/DNA and
include adaptation to an internal control, specificity between targets, specificity vs non-MG species, limit of
detection (LoD) and interference studies (co-infection and endogenous substances). The clinical data were based
on the application of the assay to clinical samples characterized by sequencing.
Conclusions: A new NAAT (nucleic acid amplification test) prototype has been developed in collaboration with the
Diagenode s.a. company, this prototype targets MG and azithromycin-resistance mutations in that pathogen.
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Background
Mycoplasma genitalium (MG) is responsible for non-
chlamydial non-gonococcal urethritis (NCNGU) in both
men and women. It is also involved in cervicitis, endomet-
ritis and pelvic inflammatory disease (reviewed in [1]). MG
is present in only 1 to 3.3% of the non-symptomatic popu-
lation [1] but its prevalence is higher in patients attending
sexually transmitted infection (STI) clinics [2–4] or female
sex workers [5]. Due to the absence of a cell wall, MG has
few antibiotic targets. Recommended first- and second-line
antibiotic treatments are azithromycin (AZM) and moxi-
floxacin respectively [1]. Treatment with doxycycline may
be attempted before treatment with pristinamycin, which
stands as the last evaluated active therapy [1, 6]. Azithromy-
cin is usually administered either as a 1 g single dose or as
500mg on day one followed by 250mg on days 2 to 5. Both
regimens are likely to induce azithromycin resistance in
MG [7, 8] as illustrated by a 100% azithromycin-resistant
MG population in Greenland, where azithromycin has been
widely used [9]. As emphasized by Wise [10], testing of
MG and of azithromycin resistance in MG is critical in
order for the clinician to select targeted antibiotic therapy
[11]. Considering the difficulty of performing MG culture
[12, 13], multiple in-house assays or commercial nucleic
acid amplification tests (NAAT) have been developed to de-
tect the presence of MG with or without macrolide resist-
ance testing. Resistance to azithromycin is mediated by
macrolide-resistance-mediating mutations (MRMM) of the
23S rRNA gene in positions 2058 and 2059 (Escherichia coli
numbering) [14] and a variety of assays have been described
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for the detection of these mutations [15–18]. Some NAATs
that base MRMM detection on additional Sanger or Pyro-
Mark sequencing have also been developed [17, 19]. We
here present and test a four-color multiplex real-time PCR
assay prototype, targeting total MG with MRMM detection
in a homogeneous assay. MRMM targets selected in this
assay account for the majority of azithromycin resistance
mutations seen in MG clinical samples. This prototype has
been developed in collaboration with Diagenode s.a. and
has served as a basis for the creation of the commercial S-
DiaMGRes in vitro diagnostic kit.
Methods
Primers and probes
The primers and probes (P/P) used in this paper were
designed in collaboration with the Diagenode s.a. com-
pany and have been integrated in the S-DiaMGRes in
vitro diagnostic (IVD) kit. Therefore, exact sequences for
these primers and probes will not be given here for intel-
lectual property reasons.
P/P for the detection of total MG specifically target
the Mg219 gene and have the same sequences as the
Mg219 P/P used in the S-DiaMGTV™ IVD kit (Diage-
node s.a., Belgium). The probe for this target is coupled
to the ROX dye.
P/P for the detection of AZM-resistant MG (mutants)
or AZM-sensitive MG (wild type, WT) were designed to
target positions 2058 and 2059 (E. coli numbering) of
the 23S rRNA gene which are known to trigger AZM-re-
sistance. The probes targeting mutations of the 2058 nu-
cleotide (A2058C, A2058G and A2058T) are coupled to
the FAM dye. The probes targeting mutations of the
2059 nucleotide (A2059C and A2059G) are coupled to
the Yakima Yellow (YY) dye. The primers are shared be-
tween the WT and each mutant, while the probes pro-
vide detection specificity.
In addition, an internal control (IC) for the entire
process from the extraction to the RT-PCR (Extraction
& Inhibition Control, or EIC: a virus, added to the sam-
ple prior to extraction) or for the PCR only (Universal
Inhibition Control, or UIC: plasmid DNA including the
EIC genomic DNA target sequence, added to the PCR
well) is detected using P/P that include a probe coupled
to the Cy5 dye. These internal controls are standard
complements to PCR IVD kits from Diagenode s.a. and
were used according to the manufacturer’s instructions.
Plasmid and genomic DNA
Plasmid DNA for each target was purchased from Gen-
Script (USA), with each target sequence inserted into a
separate pUC57 plasmid.
Genomic DNA from WT and mutant MG were pro-
vided by Dr. Jorgen Jensen (Copenhagen, Denmark)
from the following cultured strains of MG: M30 (WT),
M2300 (WT), M2321 (WT), M2341 (WT), M6302
(A2058C), M6271 (A2058G), M6604 (A2058G), M6926
(A2058T), M6303 (A2059G) and M6320 (A2059G).
Genomic DNA from non-MG species were obtained
from ATCC/LGC Standards (France).
RNA/DNA extractions
Extractions of total RNA/DNA from biological matrices
for analytical studies were processed on a MagNA Pure
MP96 automatic extractor (Roche, Belgium) according
to manufacturer’s instructions, using a MagNA Pure 96
DNA and Viral NA Large Volume 2.0 kit and the Patho-
gen Universal 500 3.1 protocol.
Extraction of total RNA/DNA from MG strain cul-
tures for analytical studies was performed using Qiagen
DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany).
The primary clinical samples had been stored at −
20 °C for up to 3 years. Swab samples were extracted
using the MagNA Pure Universal Pathogen 200 protocol
with a MagNA Pure 96 DNA and Viral NA Small Vol-
ume Kit (Roche Diagnostics A/S, Hvidovre, Denmark)
using 200 μL of the sample. Urine samples were ex-
tracted by centrifugation of 1 mL of urine in a sterile 1.5
mL Eppendorf tube at 20000×g for 15 min. The pellet
was resuspended in 200 μL sterile PBS and all 200 μL
were used for extraction, as for the swab samples.
Real-time PCR and real-time RT-PCR
Real-time PCR (analytical data on plasmid DNA) and real-
time RT-PCR (clinical data on bacteria present in clinical
samples) were both performed with the following RT-PCR
protocol: 10min at 48 °C (reverse transcription step), 7
min at 95 °C (RT inactivation / DNA initial denaturation)
and 50 amplification cycles of denaturation for 10 s at
95 °C, annealing for 15 s at 61 °C and extension for 30 s at
68 °C. RT-PCR reactions were performed using the Path-
ID™ Multiplex One-Step RT-PCR Kit master mix (Life
Technologies, Belgium) according to manufacturer in-
structions, with a total reaction volume of 25 μL per well
and a sample volume of 5 μL per well. The RT-PCR reac-
tions were performed on ABI 7500 Fast cyclers (ABI Ap-
plied Biosystems, Belgium and Denmark).
Limits of detection
The matrices used to perform limit of detection (LoD)
studies were the ESwab Liquid Amies Collection and
Transport System (Copan, Belgium) and an anonymized
mix of urine samples (Seralab, Belgium). The LoD were
calculated by performing probit analyses using Minitab
17 software (Minitab, France). Values at 95% were se-
lected as the LoD.
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Co-infection interferences and endogenous substance
interferences
The RT-PCR results of co-infection interference studies
and of endogenous substance interference studies are
interpreted according to the interference criteria summa-
rized in Table 1.
For co-infection interference studies, the reference con-
dition is the RT-PCR with only the low-concentration tar-
get in the PCR well. The test condition is the RT-PCR
with both the low-concentration target DNA and the
high-concentration interfering DNA in the PCR well.
For the endogenous substance interference studies, the
reference condition is the RT-PCR without addition of
the tested substance in the matrix. The test condition is
the RT-PCR with addition of the tested substance in the
matrix.
Testing of clinical samples
The optimized real-time RT-PCR multiplex assay with in-
ternal amplification control was tested on 43 stored anon-
ymized clinical samples received by the Statens Serum
Institut (Copenhagen, Denmark) for diagnostic testing for
MG. The internal control was added to the master mix
and not to the primary sample; thus, it was not subject to
the DNA extraction procedure. The selected samples
aimed to represent both wild-type (WT) macrolide sus-
ceptible strains and strains with macrolide resistance me-
diating mutations. Based on the routine diagnostic test
results of a pyrosequencing assay [20], the samples repre-
sented mutations as shown in Table 4, and three were
MG negative. Quantitative results were produced for both
PCR assays based on a standard curve generated from
genomic MG DNA.
Ethical considerations
There is no need for ethical approval of the study itself by
an Ethical Review Board as it involves only de-identified
samples. As samples were anonymized and were examined
here with the same purpose as they were originally submit-
ted, the study is considered quality assurance or quality de-
velopment and thus, ethics approval is not needed
according to Danish law no. 593 of 14. June 2011 with sub-




A multiplex RT-PCR targeting the 2058 and 2059 nucleo-
tides of the gene coding for the 23S rRNA was performed
to check the specificity of the P/P for their targets. The P/
P that were included in the multiplex were those targeting
the 2058 mutants MG (FAM dye), the 2059 mutants MG
(YY dye), the non-mutated WT MG (ROX dye) and the
UIC that was added to each PCR well (Cy5 dye). The
multiplex was tested against plasmid target DNA and
against genomic DNA from MG strains, each at 1250 cop-
ies/well. All wells showed a positive signal for the UIC,
validating the PCR results. For each tested DNA, a signal
was obtained in the expected channel and only in that
channel, validating the specificity of the P/P between ab-
sence of mutation (WT), mutation of 2058 nucleotide and
mutation of 2059 nucleotide (n = 3). Please note that no
A2059C MG strain was available for testing. Therefore,
the P/P for that mutation could only be tested against
plasmid DNA.
Impact of the addition of an internal control
The addition of EIC or UIC in the RT-PCR process may
affect the signal obtained for each of the targets. To
evaluate this impact, we compared 2 multiplexes. Both
multiplexes included P/P targeting the 2058 mutants
MG (FAM dye), the 2059 mutants MG (YY dye) and the
total MG (Mg219 gene, ROX dye). One multiplex (M +
IC) also included P/P targeting the UIC that was added
to each PCR well (Cy5 dye). The other multiplex (M–
IC) did not include these P/P and UIC was not added in











< 85% Any % Any ΔCt The experiment is invalid. The causes of the shift in sensitivity must be investigated and the experiment
reconducted.
≥ 85% < 85% Any ΔCt The highly-concentrated DNA or the tested substance is considered to be interfering with the detection
of the target pathogen if any of these 2 criteria are met.
Any % ΔCt≥
2SDrep
≥ 85% ≥ 85% Any ΔCt The highly-concentrated DNA or the tested substance is considered not to be interfering with the
detection of the target pathogen if both criteria are met.
Any % ΔCt <
2SDrep
% of positive calls: % of wells with target detection; ΔCt: Ct difference between reference condition and test condition; 2SDrep: 2× the standard deviation
calculated during the limit of detection study for the target concentration closest to the concentration used here
Thellin et al. BMC Infectious Diseases          (2019) 19:827 Page 3 of 8
these PCR wells. The multiplexes were tested against
plasmid target DNA, isolated (to test the amplification
of one target, as would occur in most clinical samples)
or together (to test the amplification of all of the targets
together, as would occur in a kit positive control).
Preliminary experiments were performed in the pres-
ence of UIC to determine the number of copies of target
DNA per well required to reach a Ct of 30 ± 3.3 for each
tested target, with this range of Ct corresponding to an
average signal consistent with good quality PCR curves.
These amounts of DNA were then tested with both multi-
plexes (with or without UIC, n = 6) and the ΔCt were cal-
culated. All the compared conditions provided a ΔCt ≤ 1,
validating the use of internal controls in the multiplex.
Specificity vs non-MG species
The specificity of the M + IC multiplex (2058 mutants
MG (FAM dye), 2059 mutants MG (YY dye), total MG
(Mg219 gene, ROX dye) and IC (Cy5 dye)) for MG DNA
was tested against commercial genomic DNA of the fol-
lowing bacterial, yeast and viral species: Chlamydia tra-
chomatis, Chlamydophila pneumoniae, Clostridium
difficile, Escherichia coli, Gardnerella vaginalis, Lactoba-
cillus acidophilus, Lactobacillus brevis, Lactobacillus jen-
senii, Lactobacillus reuteri, Mycoplasma arginini,
Mycoplasma pneumoniae, Mycoplasma hominis, Myco-
plasma orale, Mycoplasma salivarium, Neisseria gonor-
rheae, Neisseria meningitidis serogroup A, Neisseria
meningitidis Serogroup B, Neisseria meningitidis FAM18
serogroup C, Neisseria meningitidis M1883 serogroup C,
Trichomonas vaginalis, Ureaplasma parvum, Urea-
plasma urealyticum, Candida albicans, Candida glab-
rata, Herpesvirus 1 (HSV-1), Herpesvirus 2 (HSV-2) and
Herpesvirus 5 (CMV). These species were selected based
either on their probability of being present in clinical
samples tested for MG (AZM-resistant or not) or on
their phylogenetic proximity to MG. All wells showed a
positive signal for the UIC, validating the PCR results.
No signal for any target was obtained with any of these
non-MG species, while the positive control was positive
for each target.
Limit of detection (LoD)
The LoD at 95% (lowest number of DNA targets present
in the PCR well required to obtain detection 95% of the
time) was determined for the M + IC multiplex against
Mg219, A2058C, A2058G, A2058T, A2059G and
A2059C using target plasmid DNA at 5000, 500, 50, 5
and 0.5 copies/well. As no cultures of mutant MG were
available, we could not spike matrices of interest (urine
and ESwab) with living MG cells then extract the total
RNA/DNA and perform the RT-PCR. Instead, we ex-
tracted total RNA/DNA from these matrices previously
spiked with EIC and spiked the extract with target MG
plasmid DNA before performing the RT-PCR. As a ref-
erence, we also performed the same RT-PCR directly on
plasmid DNA in Tris-EDTA pH 8 (Ambion, Belgium)
spiked with UIC. The obtained results (see Table 2)
show LoD close to 5 copies/PCR well in most cases, with
a LoD below 50 copies/PCR well in all cases. All wells
showed a positive signal for the internal control (EIC or
UIC), validating the RT-PCR results. The sensitivity
boost provided by the additional rRNA targeting
through the reverse transcription step was tested on
total RNA/DNA extracts from MG cells. Experiments
performed on this material with or without the reverse
transcription step showed a 2–3-fold difference in target
concentration (ΔCt of 0.83 for WT targeting in single-
plex on RNA/DNA total extract from WT MG cells).
This is much lower than what was anticipated as ribo-
somes are expected to be present at 100–10,000 per cell,
and could be explained by partial RNA degradation dur-
ing handling of cells and extracts.
Co-infection interference testing
In multiplex PCR assays, competition for reagents can re-
sult in non-detection of a low-concentration target when
another target, the interferent, is present in high concen-
tration. Here, co-infection interference was tested for each
target (plasmid DNA for Mg219, A2058C, A2058G,
A2058T, A2059G and A2059C) using the M+ IC multi-
plex. EIC was added to urine and to ESwab matrices, then
total RNA/DNA was extracted from these spiked matri-
ces. Target DNA was added separately to these extracts at
5× the calculated LoD. Interferent DNA at 106 copies/
PCR well (test conditions) or extracts (controls) were
added to the wells. RT-PCR results between conditions
were analyzed based on Ct and percentage of detection
(number of wells with target detection versus total num-
ber of wells) as described in the methods. These results
are summarized in Table 3. All wells showed a positive
signal for the internal control (EIC), validating the RT-
PCR results.
Table 2 Limit of detection for each of the plasmidic DNA
targets (Mg219, A2058C, A2058G, A2058T, A2059G, A2059C),
with internal control (EIC for urine and ESwab and UIC for Tris-
EDTA). N = 6






Mg219 7.30 7.30 6.45
A2058C 23.40 6.45 6.00
A2058G 6.00 6.00 23.40
A2058T 49.85 6.00 6.00
A2059G 36.10 6.45 6.45
A2059C 5.65 6.00 6.00
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A slight interference (ΔCt = 0.61 while 2SDrep = 0.56)
was noted in urine for A2058G targeting when Mg219 is
the interferent. Strong interference was found between
mutants, entirely canceling signals for the targets at 5×
the LoD, which was expected since they share the same
primers. Also, interferences were obtained for MG219
targeting when the interferents are A2058G (ΔCt = 2.32)
or A2058T (ΔCt = 2.56) in E-Swab and A2059C (ΔCt =
1.38) in urine. This is not a problem because the MG219
target could always be detected.
Endogenous substance interference testing
Substances potentially present in tested clinical samples
can have the ability to interfere with PCR assays. In our
case, the protocol for testing of endogenous substance
interferences with the M + IC multiplex was based on
the protocol performed to validate the S-DiaMGTV™ kit
from Diagenode. Tested substances and matrices were
as follows: blood 1% in urine, albumin 1mg/ml in urine
and blood 10% in ESwab. Tested substances were added
to matrices spiked with EIC as described in the methods.
Controls consisted in similar matrices without addition
of tested substances. Total RNA/DNA was extracted and
the extracts were spiked with plasmidic DNA targets
(Mg219, A2058C, A2058G, A2058T, A2059G and
A2059C) at 5× the calculated LoD before performing
the RT-PCR. Conditions with and without endogenous
substances were compared and analyzed as described in
the methods. These results (n = 12) showed no interfer-
ence of the tested substances in any tested condition. All
wells showed a positive signal for the internal control
(EIC), validating the RT-PCR results.
Testing of clinical samples
43 clinical samples were selected based on prior routine
diagnostic pyrosequencing assay, including both azithro-
mycin sensitive MG and mutant types accounting for
the majority of azithromycin resistance mutations seen
in MG clinical samples. Distribution of sample types ac-
cording to resistance type is shown in Table 4. When
the M + IC multiplex was applied to these 43 clinical
samples, results showed a 95% fit between the M + IC
multiplex and the reference assay (Table 4). Negative
results (no target detection) in both the reference and
M + IC assays were interpreted as RNA/DNA degrad-
ation during storage of the clinical samples. Detected
discrepancies between M+ IC multiplex results and Sta-
tens Serum Institut records revealed a mutant that was
initially erroneously typed, as well as a possible mixed
infection not identified in the reference test (2058 mu-
tant + 2059 mutant in the same sample: see [b] in
Table 4). After resolving the discrepancies, the M + IC
results were 100% concordant with the reference assay.
Quantitative results (Fig. 1) produced for both PCR as-
says showed correlated data between both assays (r2 =
0.866).
Discussion
Resistance to azithromycin in MG is caused by muta-
tions of the 23S rRNA gene sequence at position 2058
and 2059 [14]. While the presence of azithromycin resist-
ant MG in the urogenital tract prior to treatment leads to
recurrent infections, the use of that antibiotic on sensitive
MG is also able to trigger such mutation-induced resist-
ance. Recent studies have shown that the prevalence of re-
sistance to macrolide treatment is rising in different parts
of the world [21–25], although this is not observed in
every study [5], and it can vary according to the studied
population [26]. In 2017, the European guideline for the
management of pelvic inflammatory disease changed the
first-line treatment from azithromycin to moxifloxacin in
cases of confirmed MG infection [27]. Tucker and Ong
[28] emphasized the usefulness of pertinent MG diagnos-
tic kits. In addition, undiagnosed MG co-infections with
other bacteria such as Chlamydia trachomatis or Neisseria
gonorrhoeae can expose MG to suboptimal azithromycin
doses, potentially leading to macrolide resistance [6].
Availability of sensitive and specific NAATs targeting MG
and its azithromycin-resistance mutations is therefore es-
sential. The four-color multiplex real-time PCR assay
prototype tested in this article has been devised to answer
that need.
The aim of the prototype was to detect both MG and 5
azithromycin-resistance mutations in the same assay. This
assay being purely based on the amplification of target nu-
cleic acids, it requires only classical primers and fluorescent
Table 3 Co-infection interference testing between the plasmidic DNA targets of the M + IC multiplex
Plasmids: 106 copies 5× LoD Mg219 A2058C A2058G A2058T A2059G A2059C
Mg219 – NI / NI NI / I NI / I NI / NI I / NI
A2058C NI / NI – SD SD I* / I* I* / I*
A2058G I / NI SD – SD I* / I* I* / I*
A2058T NI / NI SD SD – I* / I* I* / I*
A2059G NI / NI I* / I* I* / I* I* / I* – SD
A2059C NI / NI I* / I* I* / I* I* / I* SD –
X / X: in urine / in E-Swab; NI: non interfering; I: interfering; I*: strongly interfering (entirely cancels signals at 5× the LoD); −: same target; SD: same dye. n = 3
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dye-coupled probes and can be performed using classical
real-time PCR cyclers in any routine clinical lab, with no
need for additional expensive equipment or software.
Therefore, the entire set of data is obtained in a single PCR
process, without the need for additional testing such as
Sanger sequencing to detect mutations. This strategy is both
time- and cost-efficient. The specificity of the prototype for
its targets has been investigated first against both plasmid
DNA and MG genomic DNA. After validation of the detec-
tion of each of the targets, potential unwanted cross-reac-
tions were tested between targets and against genomic
material from 27 other pathogenic and commensal species
that are either potentially present in the sampling sites or
that are phylogenetically close to MG. No cross-reaction
Table 4 Description of samples used in the pre-validation of the M + IC multiplex (Diagenode MGres beta kit)
Mutation
E. coli numbering
Comment Number of samples included in study Number of samples correctly identified Sample type









A2058C Rare 4 4 4 F cervix
A2058G Most common 8 8 3 M urethra
2 M urine
3 F cervix
A2059T Very rare 0 ND
A2058T Relatively rare 9 8a 3 M urine
4 F cervix
2 F urine
A2059C Rare 2 1b 1 M urethra
1 F cervix
F female, M male, a: one sample not M. genitalium positive (both assays); b: one sample with dual populations (one with 2058 mutation and one with 2059
mutation); one misclassified in the sample selection step as it was an A2058C mutation (correctly identified by MGres)
Fig. 1 Quantitative comparison between the M + IC multiplex (Diagenode MGres beta kit) and the Statens Serum Institut reference assay
(MgPa in-house)
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was detected, allowing us then to consider the structure of
the prototype we wanted to build. It was decided for this
prototype to use different dyes for 2058 and 2059 mutations,
allowing future comparison with pyrosequencing during the
clinical validation. This also enables detection of mixed
2058- and 2059-mutated populations in a sample. The
addition of an internal control, a routine step for all IVD
kits from Diagenode s.a., to the prototype was also tested
and showed no deleterious consequences for the detection
of the targets.
The limit of detection is a critical factor to consider
when targeting pathogens such as MG, as undetected
small amounts of azithromycin-resistant MG present in
co-infections or remaining after treatment can partici-
pate in increasing the propagation of this pathogen in
the population and cause recurrent infections in the pa-
tients. Azithromycin-resistance mutations are located on
a gene coding for rRNA, it was therefore decided to use
a real-time reverse transcription PCR assay instead of a
real-time PCR assay. This resulted in an increase in the
number of potential targets in clinical samples by target-
ing both the gene coding for the 23S rRNA and the 23S
rRNA itself, increasing the sensitivity by a 2–3-fold fac-
tor. For each target in each tested matrix (urine, ESwab
and Tris-EDTA), we aimed for an optimal LoD of 5 cop-
ies/PCR, with the highest acceptable LoD of 50 copies/
PCR. This objective was reached, with most LoD being
close to 5 copies/PCR.
Interferences are other critical factors for a NAAT, and
testing of these is a required step when performing the ana-
lytical validation of such an assay. First, if one target is highly
concentrated, another target present at low concentration
can provide a negative result (co-infection interference).
When tested with our prototype, only non-problematic in-
terferences were observed between targets with different
dyes. Targets sharing the same dye could obviously not be
investigated. A second type of interference studied with our
prototype was endogenous substance interference; testing
the impact of substances known to be potentially present in
the sample, such as blood and albumin in our case, on target
detection. No such interferences were observed here.
Analytical validation could only be performed on plasmid
DNA and on genomic DNA extracted from cultures. Valid-
ation of the prototype on real clinical samples was required.
A beta-kit was provided for testing at the Statens Serum In-
stitute. When tried on a panel of 43 clinical samples, this
prototype proved at least as sensitive and specific as the in-
house NAAT + pyrosequencing protocol used routinely.
Conclusions
This study reports the analytical and clinical evaluation of
a new NAAT prototype targeting the presence of Myco-
plasma genitalium and of 2058 and 2059 azithromycin-re-
sistance mutations in that pathogen. This prototype has
been developed in collaboration with the Diagenode s.a.
company, which used it as a basis for the development of
the commercial S-DiaMGRes IVD kit. The S-DiaMGRes
kit is intended to be used as a second-line diagnostic tool
targeting MG and its 2058 and 2059 macrolide-resistance
mutations on MG-positive samples.
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